ARRIVE Working Group: Affiliations and Conflicts of Interest

- **Professor Amrita Ahluwalia, Queen Mary University of London**
  Conflicts of Interest: Editor in Chief of the British Journal of Pharmacology.

- **Dr Sabina Alam, F1000 Research**
  Conflicts of Interest: None declared.

- **Professor Doug Altman, University of Oxford**
  Conflicts of Interest: Author of the original guidelines.

- **Dr Marc Avey, ICF**
  Conflicts of Interest: None declared.

- **Ms Monya Baker, Nature**
  Conflicts of Interest: None declared.

- **Professor Bill Browne, University of Bristol**
  Conflicts of Interest: Professor of Statistics at the University of Bristol; Consults for HEFCE and the home office; Work funded by many of the UK research councils, Defra, the British Academy and the RSPCA; Serves on the Independent Statistical Standing Committee of the funder CHDI foundation; Chair of the members committee of the Cathedral Schools Trust, a multiple academy trust and a governor of Wrington Church of England primary school; Author of the original guidelines.

- **Dr Alejandra Clark, PLOS ONE**
  Conflicts of Interest: Involved in the IICARus trial.
- **Professor Innes Cuthill, University of Bristol**
  Conflicts of Interest: Author of the original guidelines.

- **Professor Ulrich Dirnagl, QUEST – Centre for Transforming Biomedical Research, Berlin Institute of Health (BIH)**
  Conflicts of Interest: None declared.

- **Dr Mike Emerson, Imperial College London**
  Conflicts of Interest: Has received funding from NC3Rs; Sits on the MRC ERPIC panel; Author of the original guidelines.

- **Professor Paul Garner, Liverpool School of Tropical Medicine**
  Conflicts of Interest: None declared.

- **Professor Stephen Holgate, University of Southampton**
  Conflicts of Interest: Trusteeship of the BLF, Kennedy Trust, DSRU and CRUK; Member of Governing Board, Nuffield Council of Bioethics; Member Science Panel for Health (EU H2020); Founder and NEB Director Synairgen; Consultant Novartis, Teva and AZ; Board Chair, NC3Rs; Chair MRC/GSK EMINENT Collaboration.

- **Professor David Howells, University of Tasmania**
  Conflicts of Interest: None declared.

- **Dr Viki Hurst, NC3Rs**
  Conflicts of Interest: NC3Rs staff, role includes promoting the ARRIVE guidelines.

- **Dr Natasha Karp, Astrazeneca**
  Conflicts of Interest: None declared.

- **Dr Catriona Maccallum, Hindawi**
  Conflicts of Interest: Shareholdings in Hindawi; On the publishing board of the Royal Society; Member of EQIPD; On the EU Open Science policy platform; Involved in the IICARus trial.

- **Professor Malcolm Macleod, University of Edinburgh**
  Conflicts of Interest: Has received funding from NC3Rs; Member of the Animals in Science Committee; Member of EQIPD; Involved in the IICARus trial.
- **Dr Nathalie Percie du Sert, NC3Rs**
  Conflicts of Interest: NC3Rs staff, role includes promoting the ARRIVE guidelines; Member of EQIPD.

- **Professor Ole Petersen, Cardiff University**
  Conflicts of Interest: Vice President of Academia Europaea; Senior Executive Editor at the Journal of Physiology; Member of the Board of the European Commission's SAPEA (Science Advice for Policy by European Academies).

- **Dr Frances Rawle, Medical Research Council**
  Conflicts of Interest: NC3Rs Board member; Shareholdings in Astrazeneca and GSK.

- **Dr Penny Reynolds, University of Florida**
  Conflicts of Interest: None declared.

- **Dr Kieron Rooney, University of Sydney**
  Conflicts of Interest: None declared.

- **Dr Emily Sena, University of Edinburgh**
  Conflicts of Interest: Has received funding from NC3Rs; Editor in Chief of BMJ Open Science; Involved in the IICARus trial; Member of EQIPD.

- **Dr Shai Silberberg, National Institute of Neurological Disorders and Stroke**
  Conflicts of Interest: None declared.

- **Dr Thomas Steckler, Janssen Pharmaceutica NV / Johnson & Johnson**
  Conflicts of Interest: Shareholdings in Johnson & Johnson; Member of EQIPD.

- **Professor Hanno Würbel, University of Bern**
  Conflicts of Interest: Member of EQIPD.